California's Ligand Teams Up With Chinese Drug Player For Hep B Treatment Aimed At 80 Million People In China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - La Jolla, California-based Ligand Pharmaceuticals is creating an alliance with Chiva Pharmaceuticals centered on a licensing agreement that will give Chiva the right to develop anti-hepatitis medicines in China, where hepatitis B has already infected more than 80 million people, and access to Ligand's technology to develop products globally for other liver ailments